Search Results for "Pemetrexed Gefitinib"
Original Source: A Study of Pemetrexed and Gefitinib Versus Gefitinib in Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to compare the combination of pemetrexed and gefitinib versus gefitinib alone, in terms of progression-free survival. This study is in participants who have stage IV non squamous NSCLC with activating epidermal growth factor mutations and who have not had any previous chemotherapy for stage IV disease.
Matching Channels
None
Matching News
Gefitinib may be superior to pemetrexed as second-line treatment for lung cancer
NEW YORK (Reuters Health) - In a Korean study of patients with advanced non-small-cell lung cancer who had never smoked and were previously treated with platinum-based chemotherapy, progression-fr...
Addition of ficlatuzumab to gefitinib may be effective in select subsets of patients with NSCLC
AVEO Oncology today announced that detailed results from an exploratory, randomized Phase 2 study evaluating the combination of ficlatuzumab, the company's HGF inhibitory antibody, and gefitinib compa...
Gefitinib Offers Modest Results in Esophageal Ca
VIENNA (MedPage Today) -- Treatment with gefitinib, a targeted EGFR inhibitor, failed to improve survival in advanced esophageal cancer but did slow disease progression, according to a study reported...
Study explains how FPGS increases effectiveness of pemetrexed in mesothelioma patients
Previous studies have hypothesized that low levels of the enzyme thymidylate synthase (TS) likely mark patients who will benefit from the drug pemetrexed - but results have been inconclusive at best a...
Malignant Mesothelioma Patients Likely To Benefit From Drug Pemetrexed Identified By Study
Previous studies have hypothesized that low levels of the enzyme thymidylate synthase (TS) likely mark patients who will benefit from the drug pemetrexed - but results have been inconclusive at best...
Skin rash may herald success of erlotinib, gefitinib in lung cancer
NEW YORK (Reuters Health) - A skin rash may be a good sign during treatment of non small-cell lung cancer with the anti-EGFR tyrosine kinase inhibitors erlotinib or gefitinib, pooled data suggest.
India dismisses AstraZeneca's patent appeal for Iressa
India's Intellectual Property Appellate Board (IPAB) has dismissed AstraZeneca's appeal concerning its previously rejected patent application for its lung cancer therapy, Iressa (gefitinib). The paten...
Study pinpoints malignant mesothelioma patients likely to benefit from drug pemetrexed
(University of Colorado Denver) Previous studies have hypothesized that low levels of the enzyme thymidylate synthase (TS) likely mark patients who will benefit from the drug pemetrexed - but results...
Matching PubMed Articles
Safety and pharmacokinetics of intrathecal administration of pemetrexed in rats.
PURPOSE: Leptomeningeal carcinomatosis is a devastating complication of malignant disease. In this study, we evaluated the safety and pharmacokinetics of intrathecally administered pemetrexed in rats....
At present, there is no standard salvage treatment strategies for lung cancer. The aim of this study is to compare the efficacies and safeties of pemetrexed alone with pemetrexed combined with oxalipl...
Pemetrexed in advanced non-small cell lung cancer.
Introduction: For patients with advanced NSCLC, treatment outcomes are still disappointing and the search for new active and safe drugs is warranted. The chemotherapeutic agent pemetrexed has produced...
Gefitinib is an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) that has been widely used for the treatment of non-small cell lung cancer (NSCLC). It is most effective in women,...
A novel, rapid and specific liquid chromatography-tandem mass spectrometric (LC-MS/MS) method was developed and validated for the simultaneous quantification of gefitinib and its predominant metabolit...
